TRISCEND II Pivotal (2020-05)
Research payments
$23,800,052
Through program year 2025, $23,800,052 in research payments was reported against TRISCEND II Pivotal (2020-05), across 1,598 payments, paid by Edwards Lifesciences Corporation.
- Paid by
- Edwards Lifesciences Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $2,045,754 | 322 |
| 2024 | Research | $4,067,624 | 389 |
| 2023 | Research | $7,395,624 | 421 |
| 2022 | Research | $7,846,055 | 327 |
| 2021 | Research | $2,444,995 | 139 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Robert Kipperman Oklahoma City, OK Named on 132 payments
- Mohamed Azeem Latib Bronx, NY Named on 79 payments
- Michael Morse Nashville, TN Named on 41 payments
- Robert Smith Plano, TX Named on 36 payments
- Justin Strote Loveland, CO Named on 34 payments
- Marcos Nores Atlantis, FL Named on 34 payments
- Pranav Loyalka Houston, TX Named on 34 payments
- Sammy Elmariah San Francisco, CA Named on 33 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.